Benzylamine-based selective and orally bioavailable inhibitors of thrombin

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 18, 1998, Pages 2563-2568

  Lee, Koo ^a   Jung, Won Hyuk ^a   Park, Cheol Won ^a   Hong, Chang Yong ^a   Kim, In Chul ^a   Kim, Sangsoo ^a   Oh, Yeong Soo ^a   Kwon, O Hwan ^a   Lee, Sung Hack ^a   Park, Hee Dong ^a   Kim, Sang Woong ^a   Lee, Yong Hee ^a   Yoo, Yung Joon ^a  

^a LG Chemical Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLAMINE; CYCLOPENTENE DERIVATIVE; LB 30057; N,N CYCLOPENTYLMETHYLAMIDE DERIVATIVE; PHENYLALANINE DERIVATIVE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HEART INFARCTION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; X RAY CRYSTALLOGRAPHY;

ANIMALS; BENZYLAMINES; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; HUMANS; KINETICS; MODELS, MOLECULAR; RATS; SERINE PROTEINASE INHIBITORS; THROMBIN;

EID: 0032558536     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00456-9     Document Type: Article

References (32)

1. 1. (a) Stone, S. R. Trends Cardiovasc. Med. 1995, 5, 134.
2. (b) Tapparelli, C.; Metternich, R.; Ehrhardty, C.; Cook, N. S. Trends Pharm. Sci. 1993, 366.
3. 2. For reviews see: (a) Das, J.; Kimball, S. D. Bioorg. Med. Chem. 1995, 3, 999.
4. (b) Edmunds, J. J.; Rapundalo, S. T. Annu. Rep. Med. Chem. 1996, 31, 51.
5. (c) Lee, K. J. Kor. Med. Chem. 1997, 6, 127.
6. 3. Kimball, S.D. Blood Coagulation and Fibrinolysis, 1995, 6, 511.
7. 4. (a) Lumma Jr., W. C.; Witherup, K. M.; Tucker, T. J.; Brady, S. F.; Sisko, J. T.; Naylor-Olsen, A. M.; Lewis, S. D.; Lucas, B. J.; Vacca, J. P. J. Med. Chem. 1998, 41, 1011.
8. (b) Misra, R. N.; Kelly, Y. F.; Brown, B. R.; Roberts, D. G. M.; Chong, S.; Seiler, S. Bioorg. Med. Chem. 1994, 4, 2165.
9. (c) Hauptmann, J; Kaiser, B. Pharmazie 1991, 46, 57.
10. (d) Angliker, H.; Wilstrom, P.; Shaw, E. Biochem. J. 1990, 266, 829.
11. (e) Hauptmann, J; Kaiser, B.; Paintz, M.; Markwardt, F. Biomed. Biochim. Acta 1987, 46, 445.
12. 5. (a) Oh, Y. S.; Kim, S. S.; Hwang, S. Y.; Yun, M. K.; Hwang, S. R.; Hong, S. W.; Lee, Y. H.; Jeong, Y. N.; Lee, K.; Shin, Y. S. EP739886-A2, 1996; Chem. Abstr. 1996. 126, 47554.
13. 5. (a) Oh, Y. S.; Kim, S. S.; Hwang, S. Y.; Yun, M. K.; Hwang, S. R.; Hong, S. W.; Lee, Y. H.; Jeong, Y. N.; Lee, K.; Shin, Y. S. EP739886-A2, 1996; Chem. Abstr. 1996. 126, 47554.
14. (b) Kim, I.-C.; Oh, Y. S.; Yun, M.; Hwang, S. Y.; Hong, S.; Lee, Y. H.; Lee, K.; Kim, S.; Yoo, Y. J.; Yoon, K. H.; Kim, D. S.; Lee, C. H. Circulation 1997, 96, I-41.
15. (c) Oh, Y. S.; Yun, M.; Hwang, S. Y.; Hong, S.; Shin, Y.; Lee, K.; Yoon, K. H.; Yoo, Y. J.; Kim, D. S.; Lee, S. H.; Lee, Y. H.; Park. H. D.; Lee, C. H.; Lee, S. K.; Kim, S. Bioorg. Med. Chem. Lett. 1998, 8, 631.
16. 6. Biotech Research Institute, LG Chemical Ltd., unpublished results.
17. 7. In Lange's Handbook of Chemistry, Dean, J. A. Ed, McGraw-Hill, New York, 1985, p 5-18.
18. 8. Sturzebecher, J.; Horn, H.; Walsmann, P.; Voigt, B.; Markwart, F.; Wagner, G. Pharmazie 1988, 43, 782.
19. 9. The detailed assay conditions are described in ref 6a and 12b.
20. 10. Kim, S.; Hong, C. Y.; Lee, K.; Lee, E. J.; Koh, J. S. Bioorg, Med. Chem. Lett. 1998, 8, 735.
21. 11. (a) Lee, K.; Hong, C. Y.; Kim, S.; Hwang, S. Y.; Hong, S. W.; Yoo, Y. J.; Lee, Y. H.; Oh, Y. S. 214th ACS National Meeting 1997, Las Vegas, NV, Abstract MEDI 64.
22. (b) Lee, K.; Hwang, S. Y.; Hong, S. W.; Hong, C. Y.; Lee, C.-S.; Shin, Y.; Kim, S.; Yoo, Y. J.; Kang, M.; Oh, Y. S. Bioorg. Med. Chem. 1998, 6, 869.
23. 11), the same intermediates as used in the synthesis of a series of benzamidrazone compounds including 1. Hydrogenation of 14 at 60 psi in the presence of methanol and a small amount of concentrated HCl afforded the desired targets as acid salts within 24 h in generally good yields. All of the compounds were purified by HPLC. (equation presented)
24. 13. Millet, J.; Theveniaux, J.; Brown, N. L. Thromb. Haemost. 1992, 76, 176.
25. 14. Male Sprague-Dawley rats (200-300 g) were used; for the oral studies the rats were fasted for 18 h. The femoral artery was cannulated with polyethylene tubing (PE-50) under light ether anesthesia. For the iv kinetic studies the femoral vein was additionally cannulated. After complete recovery from anesthesia, compounds were administered orally or intravenously. Approximately 250 μL aliquots of blood were withdrawn via the femoral artery into heparinized tube (25 U/ml) and the collected blood samples were immediately treated with methanol and zinc sulfate for HPLC analysis.
26. 15. (a) Jezyk, N.; Rubas, W.; Grass, G. M. Pharm. Res. 1992 9, 1580.
27. (b) Rubas, W.; Jezyk, N.; Grass, G. M. Pharm. Res. 1993 10, 113.
28. 16. Artursson, P. J. Phram. Sci. 1990, 79, 476.
29. 17. A manuscript for the details of these results is currently in preparation.
30. app values and drug absorption in humans, see: (a) Artursson, P.; Karlsson, J. Biochem. Biophys. Res. Commun. 1991, 175, 880.
31. (b) Rubas, W; Jezyk, N.; Grass, G. M. Pharm. Res. 1993, 10, 113.
32. (c) Yee, S. Pharm. Res. 1997, 14, 763.